Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22140414 | 0.76 | — | — | |
| SCHEMBL20320539 | 0.74 | EDNRB (0.34) | — | |
| SCHEMBL10514792 | 0.74 | IDO1 (0.36) | IDO1 | |
| SCHEMBL14480556 | 0.73 | IDO1 (0.37) | IDO1 | |
| SCHEMBL16245647 | 0.73 | — | — | |
| SCHEMBL580730 | 0.69 | — | — | |
| SCHEMBL16245733 | 0.68 | LMNA (0.33) | — | |
| SCHEMBL16935112 | 0.68 | HIF1A (0.34) | — | |
| SCHEMBL16245815 | 0.67 | RET (0.36) | — | |
| SCHEMBL14351911 | 0.66 | HIF1A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3097101-B1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10065945-B2 | Isoquinoline derivatives as MGAT2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-04 | — | — | US | disclosed |
| US-9936701-B2 | Herbicidal compounds | SYNGENTA LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9936701-B2 | Herbicidal compounds | SYNGENTA LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20180009796-A1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-01-11 | — | — | US | disclosed |
| EP-2993986-B1 | HERBICIDAL ISOXAZOLYL SUBSTITUTED PYRROLONE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| EP-3097101-A1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2993986-A1 | HERBICIDAL COMPOUNDS | Syngenta Participations AG (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-20160066574-A1 | Herbicidal Compounds | SYNGENTA LIMITED (GB) | 2016-03-10 | — | — | US | disclosed |
| US-20160066574-A1 | Herbicidal Compounds | SYNGENTA LIMITED (GB) | 2016-03-10 | — | — | US | disclosed |
| WO-2014180740-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-11-13 | — | — | WO | disclosed |
| US-6541498-B2 | Antiinflammatory agents, antiasthmatics | TEXAS BIOTECHNOLOGY | 2003-04-01 | — | — | US | disclosed |
| US-6376523-B1 | HYPOTENSIVE AGENTS; ANTIINFLAMMATORY AGENTS; ENDOGENOUS VASOCONSTRUCTION PEPTIDE | TEXAS BIOTECHNOLOGY CORPORATION | 2002-04-23 | — | — | US | disclosed |
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
| EP-1069114-A2 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6030991-A | ADJUSTING THE BINDING OF AN ENDOTHELIN PEPTIDE TO ENDOTHELIN A OR, PARTICULARLY, ENDOTHELIN B RECEPTORS, I.E. INHIBITING OR STIMULATING; ANTIINFLAMMATORY AGENT; ASTHMA; KIDNEYS; GASTROINTESTINAL, CARDIOASCULAR DISORDERS; HYPOTENSIVE AGENTS | TEXAS BIOTECHNOLOGY CORP. (US) | 2000-02-29 | — | — | US | disclosed |
| US-5571821-A | CARDIOVASCULAR DISORDERS TO MODULATE ENDOTHELIN, HYPOTENSIVE AGENTS AND VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-11-05 | — | — | US | disclosed |
| US-5514691-A | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin | IMMUNOPHARMACEUTICS, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009796-A1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MGAT2, MGAT1, ACAT2 | IDO1 1428/4885 |
| US-20160066574-A1 | Herbicidal Compounds | CBR3, DDT, RDX | IDO1 1322/4885 |
| US-10065945-B2 | Isoquinoline derivatives as MGAT2 inhibitors | MGAT2, MGAT1, ACAT2 | IDO1 1428/4885 |
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | EDNRB, EDNRA, ECE1 | IDO1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.